Pharmaceutical giant Pfizer (NYSE:PFE) closed out 2011 with the loss of its biggest selling drug and one of the best-selling drugs in history. Despite the loss, the company is still reporting billions in profits and offers a decent combination of appealing valuation, above-average dividend, and respectable expected profit growth in the coming years. (For related reading, see Investing In The Healthcare Sector.)

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Full-Year Recap
Total sales eked out 1% growth to $67.4 billion and consisted of a 2%, or $1.6 billion decline in organic growth that was boosted by 3% in benefits, or $1.9 billion, from positive foreign currency fluctuations. U.S. sales struggled, falling 7% to $26.9 billion, or nearly 40% of total sales. International sales accounted for the remaining $40.5 billion and advanced 6%, though foreign exchange fluctuations boosted that total by 5%. Fourth quarter sales fell 4% to around $16.7 billion to reflect the loss of flagship drug cholesterol-lowering drug Lipitor, which lost patent protection in November 2011.

Pre-tax income advanced 6% to $8.7 billion for a very healthy margin of 12.9% of sales. The improvement reflected a 3% reduction in research and development (R&D) expense to $9.1 billion, reduction in restructuring and other charges, though income tax expense jumped nearly threefold to $4 billion. A gain from a discontinued business pushed reported net income to $10 billion, or 21% ahead of last year's figure. Share buybacks boosted earnings per diluted share by 25% to $1.27.

Outlook
For the coming year, Pfizer expects to report sales in a range of $60.5 billion and $62.5 billion for an annual decline of between 7-10%. It expects to report earnings between $1.37 and $1.52 per diluted share, but adjusted EPS in a range of $2.20 and $2.50. It also anticipated operating cash flow of $19 billion. (To learn more about understanding earnings outlook, read Earnings Forecasts: A Primer.)

The Bottom Line
After years of anticipation, 2011 finally saw the loss of Lipitor, which was a huge sales and profit driver for Pfizer. The company has moved aggressively to sell Lipitor at a lower price point and directly to consumers to attempt to not lose all the related revenue, but the sales will be a fraction of the $10.7 billion in sales that Lipitor reported in 2010.

As with rivals that include Eli Lilly (NYSE:LLY), Merck (NYSE:MRK) and Forest Laboratories (NYSE:FRX), Pfizer faces a continued wave of drug patent expirations in the next few years. Despite the pressure to sales, it should be able to maintain decent annual profit gains through a combination of cost-cutting efforts and new product introductions. For instance, the recently approved FDA drug Eliquis, for the treatment of atrial fibrillation that is being developed along with Bristol-Myers Squibb (NYSE:BMY), could see sales of over $4 billion by 2017, according to estimates by industry analysts.

At a forward P/E of below 10 and current dividend yield of around 4.1%, Pfizer offers a decent combination of a reasonable valuation and income for investors. Again, sales growth will be lacking for the foreseeable future, but Pfizer is still very profitable and has ample cushion to adjust its cost structure to maintain a respectable level of profit gains going forward. (For additional reading, see Evaluating Pharmaceutical Companies.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  7. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  8. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  9. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  10. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center